Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol

This article was originally published in The Pink Sheet Daily

Executive Summary

The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.

You may also be interested in...



Mylan's Nebivolol Is "Approvable" At FDA

The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.

Mylan's Nebivolol Is "Approvable" At FDA

The beta blocker's user fee date had been extended by three months following submission of additional analysis. Mylan expects the anti-hypertensive to be the cornerstone of its brand division.

Mylan Reaffirms Commitment To Brand Business Growth Despite King Setback

The company will continue to explore acquisition opportunities, CEO Coury says, noting King was not "the only option." Mylan is not yet discussing whether it will launch and market nebivolol on its own or seek a partner for the cardiovascular agent; J&J holds a "right to consent" to any partner.

Related Content

Topics

UsernamePublicRestriction

Register

PS060123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel